StockNews.AI
ALDX
StockNews.AI
120 days

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Aldeyra Therapeutics, Inc. - ALDX

1. Pomerantz LLP is investigating potential securities fraud involving Aldeyra. 2. The FDA issued a Complete Response Letter regarding reproxalap's NDA on April 3, 2025. 3. Aldeyra's stock plummeted 73.31% to $1.42 after the FDA's announcement. 4. The FDA expressed concerns over trial data and lack of demonstrated efficacy. 5. Investors are advised to consider potential class action participation.

4m saved
Insight
Article

FAQ

Why Very Bearish?

Aldeyra's lack of FDA approval and imminent legal investigations significantly undermine investor confidence, likely leading to further stock price declines.

How important is it?

The investigation into fraud and FDA rejection presents serious risks for ALDX's future performance, prompting heightened scrutiny and negative market sentiment.

Why Short Term?

The immediate impact is observed due to the FDA response affecting current investor sentiment and ongoing legal inquiries may take time to resolve.

Related Companies

AMGNVRTXREGN
NEW YORK, April 21, 2025 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of  Aldeyra Therapeutics, Inc. (“Aldeyra” or the “Company”) (NASDAQ: ALDX).  Such investors are advised to contact Danielle Peyton at newaction@pomlaw.com or 646-581-9980, ext. 7980. The investigation concerns whether Aldeyra and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices.  [Click here for information about joining the class action] On April 3, 2025, Aldeyra issued a press release “announc[ing] receipt of a Complete Response Letter from the U.S. Food and Drug Administration (FDA) for the resubmission of the New Drug Application (NDA) of reproxalap, an investigational drug candidate, for the treatment of dry eye disease.” The press release specified that “[a]lthough no manufacturing or safety issues with reproxalap were identified, the FDA stated in the letter that the NDA ‘failed to demonstrate efficacy in adequate and well controlled studies in treating ocular symptoms associated with dry eyes’ and that ‘at least one additional adequate and well controlled study to demonstrate a positive effect on the treatment of ocular symptoms of dry eye’ should be conducted.” The press release further stated that “[t]he letter identified concerns with the data from the trial submitted to the NDA that may have affected interpretation of the results, which the FDA stated may be related to methodological issues, including a difference in baseline scores across treatment arms.” On this news, Aldeyra’s stock price fell $3.90 per share, or 73.31% to close at $1.42 per share on April 3, 2025. Pomerantz LLP, with offices in New York, Chicago, Los Angeles, London, Paris, and Tel Aviv, is acknowledged as one of the premier firms in the areas of corporate, securities, and antitrust class litigation. Founded by the late Abraham L. Pomerantz, known as the dean of the class action bar, Pomerantz pioneered the field of securities class actions. Today, more than 85 years later, Pomerantz continues in the tradition he established, fighting for the rights of the victims of securities fraud, breaches of fiduciary duty, and corporate misconduct. The Firm has recovered numerous multimillion-dollar damages awards on behalf of class members. See www.pomlaw.com. Attorney advertising. Prior results do not guarantee similar outcomes.    CONTACT: Danielle PeytonPomerantz LLPdpeyton@pomlaw.com646-581-9980 ext. 7980

Related News